SAN FRANCISCO (TheStreet) -- It's rare to hear a biotech CEO mention a competing company by name when speaking in public. Like politicians, CEOs would rather acknowledge their rivals with generalities. BioMarin Pharmaceuticals (BMRN - Get Report) CEO Jean-Jacques Bienaime feels differently because he just went directly after Sarepta Therapeutics (SRPT - Get Report) at the J.P. Morgan Healthcare Conference.
Included in Bienaime's investor presentation is two slides making a direct data comparison between BioMarin's (soon to be) Duchenne muscular dystrophy drug drisapersen and Sarepta's competing DMD drug eteplirsen. The still-experimental drugs have never been studied head to head in a clinical trial, of course, but that didn't stop BioMarin from attempting to show how drisapersen was more effective than eteplirsen.